This review summarizes the role of the monocytic responses to lipopolysaccharide as it relates to periodontal disease severity. Data are presented which illustrate that the levels of prostaglandin E 2 (PGE 2 ) secreted by systemic peripheral blood monocytes in culture, in the presence of bacterial endotoxins, are highly correlated with the levels observed in the gingival crevicular fluid. Furthermore, the different periodontal diagnostic categories have varying levels of monocytic and crevicular fluid PGE 2 , in juxtaposition with clinical disease severity. These data are consistent with the concept that there is close synchrony between the systemic responsiveness of peripheral blood monocytes with regard to prostanoid synthesis and the local levels of mediator present within the gingival crevice.
In recent years an altered central dogma regarding the pathowhich the host response emerges as the dominant effect modifier in disease expression. Recent molecular and cellular data genesis of periodontitis has emerged [1, 2] . Periodontal diseases are widespread, but severe disease appears to affect only have improved our understanding of the inflammatory and immune mechanisms that result in the destruction of connective 7% -14% of the population [3] . Periodontitis is multifactorial in nature with regard to potential etiologic factors and effect tissue, including ligament and bone. This sequence can be considered a central pathway that is common to most forms of modifiers. Since the classic 1965 article by Löe et al. [4] , the microbial plaque has been considered the cause of periodontal disease but is activated or inhibited to varying degrees by various components of the host response and exposure factors. diseases. Although certain gram-positive organisms have been associated with disease, the preponderance of data indicates This pathway can be activated in cyclic fashion, as manifested by clinical progression or remission of disease activity. The that the gram-negative anaerobic species are the dominant pathogens [5] . However, recent data support the concept that central pathway that links microbial exposure to connective tissue destruction involves monocytic (Mf) activation. microbial plaque is a necessary etiologic factor that is at the origin of the causality pathway but it is not sufficient to explain
In this model the monocytic activation by lipopolysaccharide (LPS; endotoxin) is a critical regulatory event that ultimately the presence, absence, or severity of disease. It is likely that one or more virulent clonal types of periodontal pathogens modulates connective tissue catabolism. The purpose of this article is to summarize the data regarding the role of monocytic within the microbiota effectively evade host defenses to present an invasive challenge. Once the defenses are challenged, howsecretion of prostaglandin E 2 (PGE 2 ) in various forms of periodontal diseases. New data are shown linking the local monoever, the quality of the host immunoinflammatory response appears to ultimately determine the severity and extent of discytic production of PGE 2 within the periodontal tissues (as measured in the gingival crevicular fluid, or GCF) and the ease expression.
The difference among people in terms of the nature of the responsiveness of systemic monocytes (as determined with use of peripheral blood monocytes in culture). Evidence is provided immunoinflammatory response is a potential determinant of the variability in the expression of disease observed within the to suggest that the monocytic responsiveness to LPS, as reflected in the amount of PGE 2 secreted, may be a key regulator population. The current concepts of pathogenesis have extended the model from a plaque-dominated process to one in of disease expression. Furthermore, the magnitude of the monocytic responsiveness is simultaneously expressed locally and systemically. This coordination of monocytic conditions in the periodontal and systemic blood compartments suggests a sys-affinity receptor for the LPS -LPS binding protein complex. tent with an altered microbial burden and increased susceptibility to further breakdown. As expected, at moderate to deep When activated CD14 initiates a complex signaling cascade, phospholipase A 2 is activated to release arachidonic acid plus (i.e., 4 -11 mm) periodontal sites in patients with AP, there is a significant elevation in GCF-PGE 2 levels as compared with lysophospholipids from membrane phospholipid pools. Arachidonic acid is subsequently converted by the action of a cyclothose at shallow sites (71.0 { 11.8 ng/mL vs. 49.0 { 5.2 ng/mL). Furthermore, the mean GCF-PGE 2 level in patients in oxygenase (PGH 2 synthase) to PGE 2 , which appears extracellularly. Transcriptional regulatory factors are activated and whom periodontal disease progression is detected, as defined by attachment loss of §3 mm at one or more sites over a 6-ultimately result in the transcription, synthesis, and secretion of several proinflammatory molecules, such as IL-1b, TNF-a, month period after initial therapy, is significantly higher than in subjects who have no clinical signs of disease activity (113.4 and IL-6. These four mediators target monocytes and fibroblasts to secrete matrix metalloproteinases to degrade collagen { 9.0 ng/mL vs. 50.1 { 7.1 ng/mL; P õ .00001). This observation holds true at the time of detection of attachand glycosaminoglycans, thereby destroying the ligament and extracellular matrix. These mediators also act directly on bone ment loss as well as 6 months before this time point. Furthermore, at sites undergoing periodontal attachment loss, the GCFcells to induce osteoclast formation and activation.
Clinically, activation of this pathway ultimately results in PGE 2 level is 305.6 { 56.5 ng/mL, showing a fivefold to sixfold elevation in comparison with the level at nonprogressing sites. increased attachment and bone loss. Activation of this pathway can be detected biochemically, prior to any clinical sign of Thus, biochemically the GCF-PGE 2 level represents a continuum from health to progressing disease as the PGE 2 level inperiodontal disease progression. Furthermore, experimental disruption in the central components of this host pathway abates creases from Ç30 ng/mL to 300 ng/mL, a 10-fold increase in mediator level. Levels above 60 -100 ng/mL reflect increased clinical disease progression [4] . It should be emphasized that this description of an LPS-triggered cascade of events is a risk or subclinical destruction. However, these values refer to normal, otherwise healthy people who have either gingivitis or great oversimplification of a complex series of occurrences and divergent pathways.
AP. Some patients, such as those with diabetes or early onset disease, appear to have an altered GCF-PGE 2 profile, which is If one is to test this model of pathogenesis, then logically the differences in disease expression observed in different people consistent with increased risk for disease progression and a parallel upregulated systemic monocytic state. should be reflected in the relative degree of pathway activation. In this report we focus on the monocytic release of PGE 2 in response to LPS, examining the differences in PGE 2 -release profiles among patients with various forms of disease and in GCF-PGE 2 in High-Risk Patients health.
An exaggerated GCF-PGE 2 inflammatory response has been documented in several high-risk patient groups, as compared PGE 2 and Periodontal Disease Activity and Severity to that among otherwise healthy patients with gingivitis and AP [9, 11] . These high-risk categories include patients with Since original reports in 1986, considerable additional data have confirmed that the PGE 2 level within the gingival creviearly onset periodontitis (EOP), refractory periodontitis (RefP; American Academy of Periodontology [AAP] type V), insulincular fluid can be considered a reliable biochemical marker for periodontal disease activity and severity [6 -9] . During dependent diabetes mellitus (IDDM) -associated AP (IDDM-AP), and terminal dentition periodontitis (TDP, i.e., extremely the induction of experimental gingivitis in humans, there is an increase in PGE 2 levels in GCF (GCF-PGE 2 levels), from severe periodontitis requiring multiple extractions). Thus, these subjects with different forms of disease seemed to share a 20.5 { 7.6 ng/mL (mean { SE, periodontal health) to 53.5 ng/mL after 4 weeks [10]. This GCF-PGE 2 level determined propensity for developing severe forms of periodontal disease and also had elevated GCF-PGE 2 levels. This observation at 4 weeks is comparable to that measured cross-sectionally among patients with adult periodontitis (AP; 58.7 { 11.2 prompted us to examine whether the production of PGE 2 by peripheral blood monocytes from these patients may be enng/mL) [10, 11] and is coincident with the attainment of clinical inflammation. Thus, in a cross-sectional comparison, hanced in response to LPS challenge, as compared with such production in periodontally healthy individuals. the GCF-PGE 2 level expressed as a mean patient value does not seem to be a sensitive discriminator between established
The underlying hypothesis was that monocytes from patients who had more severe disease or were actively losing attachment gingivitis and stable or nonprogressing AP.
Furthermore, if one considers only shallow periodontal sites at the time of sampling would secrete more inflammatory markers (with PGE 2 as a representative mediator) than would mono-(i.e., 0 -3 mm) in patients with AP, the GCF-PGE 2 levels are significantly higher than those of healthy subjects (49.0 { 5. 2 cytes from subjects with less severe forms of disease, inactive disease, or no disease. We hypothesized that this would be ng/mL vs. 20.5 { 7.6 ng/mL). Thus, periodontally healthy sites in patients with AP have higher GCF-PGE 2 We also hypothesized that the systemic responsiveness of TDP included eight with AP and eight with generalized EOP, according to the EOP criteria of Gunsolley et al. [14] . Finally, these monocytes would regulate the amount of PGE 2 produced locally in the periodontal pocket, as measured in the GCF. The the last group of interest included 13 patients with paroxysmal nocturnal hemoglobinuria [15] , a condition in which patients half-life of gingival monocytic cells is about 18 days. Thus, any systemic basal responsiveness would be expected to evenlack monocytic CD14 because of an impaired ability to synthesize the glycerolphosphatidyl inositol anchor protein that tually be manifest locally, since LPS is an omnipresent challenge in the subgingival periodontal pocket. For this reason, attaches the CD14 receptor onto the cell membrane. Thus, monocytes from these individuals lack the membrane-bound, we also examined the potential association between the levels present within the GCF compartment and that produced by high-affinity LPS -LPS binding protein receptor, CD14. As will be shown and appears elsewhere [15] , monocytes from monocytes in culture upon LPS stimulation at a fixed suboptimal concentration (0.03 mg/mL). In effect, we sought to test these individuals have an impaired ability to respond to bacterial endotoxin with respect to mediator production. our 1993 hypothesis that the patient's monocytic mediator response to LPS challenge was a key determinant of disease expression [12] .
GCF Sampling and Analysis

Materials and Methods
GCF was collected with Periopaper filter strips (Pro Flow,
Patient Selection
Amityville, NY), and the volume was quantitated with a calibrated Periotron 6000 instrument (Pro Flow). The concentration This report includes data from a total of 209 subjects diof PGE 2 within the GCF was determined by means of RIAs vided into 7 main diagnostic categories: health (n Å 34), AP or ELISAs. Since the procedures for GCF collection, storage,
and analysis have previously been described [8, 16 -18] , only TDP (n Å 16; discussed below), and paroxysmal nocturnal a brief summary of the sampling technique and analysis is hemoglobinuria (n Å 13). All patients except those with presented. The interproximal area between the two most poste-IDDM-AP or paroxysmal nocturnal hemoglobinuria were free rior teeth in each quadrant was selected for GCF sampling. of systemic conditions or medications known to affect inFour filter strips, one in each quadrant, were used for each flammatory or periodontal status. Some data from most of patient. The preselected sites were isolated with cotton rolls these patients have been reported previously [6 -8, 10 -13] .
and air-dried, and then the GCF filter strips were placed into This report provides a reanalysis of previous data and a master the periodontal pocket until visibly moistened. After their recompilation of existing patients, including new patients added moval, the volume was determined with the Periotron 6000. since our original publications. Specifically, data demonstraImmediately afterward, the collected samples were wrapped in ting dose-response curves between LPS concentration and aluminum foil, placed into screw-top cryovials, and transferred monocytic secretion of PGE 2 have been published for 21 into liquid nitrogen. All GCF samples were maintained in liquid healthy patients [8] , 21 patients with AP [8] , 25 patients with nitrogen until the assays were performed. Prior to assay, each IDDM-AP [8] , and 16 patients with TDP [9] . For the purposes filter strip was eluted and independently analyzed for PGE 2 , of this report, data concerning monocytic release of PGE 2 expressed as a GCF-PGE 2 concentration in ng/mL. The mean are shown for the different patient groups using a single, GCF-PGE 2 concentration for each patient represents the aversubmaximal LPS concentration for stimulating Mf in culture, age for four sites. adding new patients to the previously published data set.
The subjects with EOP include 22 patients who met the criteria described by Gunsolley et al. [14] . Patients with AP were subdivided according to type of disease (AAP types I to
Monocyte Isolation and Stimulation with LPS
IV) and by the pooling of types I and II (n Å 36) as well as types III and IV (n Å 30), on the basis of similarities in GCF The monocytic secretion of PGE 2 in the peripheral blood of each patient was evaluated following monocyte isolation, and monocytic secretory patterns. RefP (AAP type V) is defined by Collins et al. [13] . Patients with IDDM-AP (AAP culturing in the presence of LPS, and determination of PGE 2 concentration in the supernatant, with use of the methods detypes I and II [n Å 9] and types III and IV [n Å 25]) are characterized in detail elsewhere [14, 15] . Recently, a new scribed earlier [8, 9, 16] . A standard venipuncture technique was used to collect Ç40 mL of whole blood in heparinized periodontitis category has been suggested: TDP, as adapted from the prosthodontic literature [9] . This refers to extremely tubes, and mononuclear cells were isolated with use of FicollHypaque density gradients (Sigma Chemical, St. Louis), folsevere forms of AP and EOP that are at a transition stage between severe periodontitis and edentulism. Basically, these lowed by adherence to plastic culture wells. presence of tritiated arachidonic acid, and the release of PGE 2 was monitored by extraction, separation by HPLC, and quantitation by scintillation counting. The release of radioactive PGE 2 into the media from unstimulated monocytes is shown in figure were resuspended in RPMI medium in the presence of a 10% pooled human antibody serum source of LPS-binding protein 1. As can be seen, the basal secretion of PGE 2 in patients with EOP and RefP is significantly higher than that in healthy and 1% penicillin/streptomycin at 37ЊC in 5% CO 2 . Isolated monocytes were placed in short-term culture with varying subjects or patients with AP. There is no difference in the level of PGE 2 secreted in healthy controls vs. patients with AP. Thus, amounts of LPS (Porphyromonas gingivalis and Escherichia coli, over a dose-response range of 0.003 to 3.0 mg/mL) for freshly isolated, unstimulated monocytes in subjects with EOP or RefP appear to be ''activated or primed'' in the peripheral PGE 2 quantitation. The supernatants were harvested after overnight incubation (12 -18 hours) and analyzed by RIA or ELISA blood of these subjects, as compared with such monocytes in healthy subjects or those with AP. This is reflected in the for the amount of PGE 2 present.
In certain experiments, monocytes were preincubated with approximate ninefold to 10-fold elevation of monocytic PGE 2 in the absence of exogenous LPS. tritiated arachidonate -human serum albumin conjugate. This resulted in uptake of arachidonate into preexistent phospholipid Furthermore, monocytes from patients with EOP or RefP secrete more PGE 2 in response to LPS challenge throughout pools. Following LPS stimulation, supernatants from these labeled cells were subjected to reverse-phase high-pressure liquid the entire dose-response curve (figure 2), as compared to AP or healthy controls. In these data, the elevated PGE 2 secretion chromatography (HPLC), and the amount of radiolabeled PGE 2 was determined with an in-line scintillation counter, as dethroughout the LPS dose-response appears to be largely due to differences in basal secretion. In this early experiment and scribed earlier [19] . In brief, adherent monocytes were released (0.01 mM EDTA-PBS [pH, 7.4] at 4ЊC) and pelleted. Cells in subsequent experiments, no significant difference in the monocytic release of PGE 2 has been observed in terms of the were prelabeled by incubating with 3 H arachidonic acid -human serum albumin conjugate in RPMI medium, washed, and response in healthy patients or those with gingivitis vs. patients with moderate to severe AP. However, in both EOP and RefP, replated at 10 8 cells/mL in RPMI medium supplemented with 10% pooled antibody serum (Sigma, St. Louis) and 1% penicilthere is an increase in the maximum level secreted (about twofold to threefold) and a shift to the left in the dose-response lin/streptomycin. After incubation, monocyte supernatants were extracted as described by Powell [19] . To each sample, curve. This indicates not only that monocytes from these two patient groups secrete higher levels of PGE 2 but that low levels 10,000 counts per minute (cpm) of 3 H-6K-PGF1a was added as internal standard. To 0.5 mL of media, 1.0 mL of ethanol of LPS, which are below the activation threshold of control or AP monocytes, trigger PGE 2 secretion in these subjects. Thus, was added and centrifuged.
The pellet was washed with 0.5 mL of ethanol, the supernaeven relatively low levels of endotoxin might be expected to result in PGE 2 secretion in the GCF in these individuals. tants were pooled, and the sample was adjusted with water to 15% ethanol, with a final volume of 15 mL. Acetic acid was This early observation led to a series of experiments involving many different groups of patients to determine whether this added to a pH of 3.0, and the sample was passed over a precon-duced monocytic secretory capacity and secrete only 28.5 { 5.8 ng of PGE 2 per mL (P õ .00002, in comparison with the level for pooled Mf N subjects). This is designated as a Mf 0 trait for these CD14-deficient subjects. The GCF-PGE 2 levels for the Mf N subjects are consistent with the local increase in bacterial burden associated with AP of AAP types I -II (44.4 { 5.8 ng/mL) and III -IV (58.7 { 11.2 ng/mL).
This finding suggests that the significantly lower GCF-PGE 2 levels seen in healthy persons (22.5 { 4.8 ng/mL) than in pooled subjects with AP of AAP stages I -IV (P õ .002) are a reflection of the lower LPS burden associated with optimal periodontal health. It is interesting that a reasonable linear correlation exists among the patients and that the healthy individuals are outliers at this particular LPS concentration. This and EOP, are considered. These more aggressive forms of systemic monocyte responsiveness trait, as determined by the amount of PGE 2 secreted in culture, could be correlated to the severity of the condition and the level of PGE 2 present within the GCF. This experiment was conducted by generating LPSdose vs. PGE 2 -response curves for each subject and simultaneously measuring the PGE 2 level within the GCF, averaging over four sites per subject. To permit easy comparison among patients, the data are shown for the monocytic PGE 2 level at only one suboptimal LPS concentration (0.03 mg/mL) vs. the GCF-PGE 2 level. These data are developed sequentially in figure 3. It should be noted that the monocytic secretion of IL1b and TNF-a has also been investigated in some of these patients and is reported on elsewhere [8, 9, 16] . These data are not presented in this report but in general show the same trend as PGE 2 responses. EOP (102.6 { 18.4 ng/mL; P õ .001). Furthermore, LPSstimulated monocytic PGE 2 levels for both TD-AP (145.0 { ng/mL) is significantly greater than that in healthy subjects or patients with AP (P õ .01, vs. pooled Mf N subjects). This 20.7 ng/mL) and TD-EOP (180.6 { 47.6 ng/mL) patients are greater than those for patients with moderate/severe AP (68.4 systemic monocytic trait appears stable, since the level of secretion remains elevated in controls with AP following treatment { 7.4 ng/mL; P õ .001) or EOP (90.0 { 7.6 ng/mL; P õ .05). It is interesting to note that the relationship between [6] , and the term hyperresponsive monocytic trait (or Mf / trait) has been used [11] to characterize this upregulated systemic local and systemic PGE 2 response appears to maintain a similar ratio or slope as the severity of disease escalates. monocyte characteristic.
The highly significant elevations in levels of GCF-PGE 2 Finally, figure 3 illustrates the responses of the subjects with IDDM-AP, subdivided by AAP stages (I -II and III -IV). These (RefP: 104.0 { 13.1 ng/mL; EOP: 102.6 { 18.4 ng/mL) relative to those in pooled subjects with AP of AAP stages I -IV data from an earlier publication [8] demonstrate a significant 4.2-fold elevation in GCF-PGE 2 level in a comparison of dia-(P õ .00006 for RefP and P õ .0007 for EOP) also are consistent with the rapidly progressive and active clinical courses of betics with AP of AAP stage I -II (183.2 { 76. ng/mL) to periodontally matched, nondiabetic subjects (43.3 { 8.1 these conditions. These subjects are at high risk for clinical breakdown compared with the risk for subjects with AP. It is ng/mL) (P Å .003). A higher, 7.4-fold elevation is observed in a comparison of GCF-PGE 2 levels for patients with IDDMinteresting that the ratio between systemic and local responses remains identical for these subjects, in contrast with the ratios AP of AAP stage III -IV (319.1 { 62.2 ng/mL) and those for periodontally matched nondiabetics (42.9 { 11.9 ng/mL) for subjects with AP. This can be noted in figure 3 , in which all of these diseased subjects fall on the same linear regression (P Å .0002). Among diabetics, the GCF-PGE 2 level is significantly elevated for those with moderate-severe periodontitis, line. In this regard, the observed GCF-PGE 2 level might be anticipated on the basis of the systemic monocytic response as compared with that for patients with gingivitis/mild periodontitis (P Å .01). Diabetics as a group show a 13.8-fold trait.
The combination of these five patient groups establishes a elevation in GCF-PGE 2 level over the level for periodontally healthy persons and a 6.6-fold elevation over that for nondiaclear, positive association between local and systemic PGE 2 responses, as evident in figure 3. Using the mean values from betics with moderate-severe periodontitis (P õ .00001). These data clearly suggest that IDDM results in a dramatic elevation these five patient groups as point estimates to compute the linear regression curve for the association between GCF-PGE 2 in the GCF-PGE 2 levels, irrespective of periodontal status. and monocytic (''mono-'') PGE 2 (at 0.03 mg of P. gingivalis LPS per mL) provides the following equation: Discussion Data regarding cultured peripheral blood monocytes from Log 10 [GCF-PGE 2 ng/mL] Å 0.01 1 [mono-PGE 2 ng/mL] high-risk patients (with EOP, RefP, IDDM-AP, and TDP) sug-/ 1.0, with r Å 0.997 and r 2 Å 0.995 (P Å .0001). gest that the locally elevated GCF-PGE 2 levels are associated with a systemically upregulated monocytic PGE 2 trait. These Thus, incremental changes in the systemic monocytic response observations confirm and extend previous investigations sugare reflected as exponential changes in the local GCF-PGE 2 gesting that patients with RefP [20, 21] and EOP [22] have levels.
considerably elevated monocytic PGE 2 levels as compared with those in patients with AP. In 1989 Garrison and Nichols [20] demonstrated that LPS-stimulated monocytes from ''periodon-
Monocytic and GCF-PGE 2 Responses in TDP and IDDM-AP
Figure 3 also illustrates the local and systemic responses of titis-susceptible'' subjects secreted twofold to threefold more PGE 2 than those from ''periodontitis-resistant'' patients. In this patients with severe AP and generalized EOP at a terminal dentition (TD) stage. The periodontal status of these subjects context the term susceptible was used to describe cases of RefP, whereas the term resistant referred to patients with untreated is reflected in the severity scores (mean clinical attachment levels, only among sites for which the scores were §4 mm) periodontitis who had poor plaque control and little or no disease. Shapira et al. [22] observed significantly greater basal of 6.03 { 0.33 mm for TD-AP and 6.11 { 0.42 mm for TD-EOP. Recent data by Salvi et al. [9] have provided evidence levels (no LPS challenge) of monocytic inflammatory mediators, including PGE 2 , in 28 patients with EOP than in periodonthat patients with TD-AP and TD-EOP have exaggerated GCF and monocytic secretions of several inflammatory mediators, tally healthy controls. Furthermore, these investigators found a consistent threefold to fivefold greater monocytic PGE 2 secreincluding PGE 2 , as compared with secretions in patients with AAP type IV periodontitis. Data from that investigation illustion throughout the LPS dose-response curve than that in control subjects. Thus, these earlier observations have now been trate that the GCF has unexpectedly high levels of PGE 2 in both TD-AP (970.5 { 154.7 ng/mL) and TD-EOP (749. ) occurs spontaneously systemic steroids to manage the clinical course of paroxysmal nocturnal hemoglobinuria, excluding these subjects from this and throughout the LPS dose-response range. The systemic monocyte in RefP and EOP appears to be ''primed'' in that it dataset does not significantly alter the data, and the monocytic responses in this culture assay are not different in a comparison synthesizes greater amounts of PGE 2 in culture, even in the absence of LPS challenge, as compared with amounts syntheof patients taking steroids and those who were not (details appear in [15] ). sized in healthy controls or subjects with AP. Although not shown in figure 2 , additional findings by Salvi et al. [8] indicate
In contrast to the molecular mechanisms responsible for the observed Mf / trait in EOP, RefP and IDDM-AP are not presthat systemic monocytes in subjects with IDDM also appear to be primed in the circulation. Freshly isolated unstimulated ently understood. Nonetheless, several potential explanations have emerged and include the following. peripheral blood monocytes from patients with IDDM secrete higher amounts of PGE 2 than do those from nondiabetic con-(1) Mølvig and colleagues [23] have demonstrated stable interindividual differences in monocytic release of IL-1b, TNFtrols. Basal monocytic PGE 2 levels in diabetics with gingivitis/ mild periodontitis (75.0 { 32.0 ng/mL) and moderate/severe a, and PGE 2 in response to LPS. Thus, there is a wide spectrum in the magnitude of the inflammatory-mediator release among periodontitis (104.0 { 21.0 ng/mL) are higher than those in control subjects with moderate/severe AP (57.1 { 5.6 ng/mL). different individuals. This response trait appears to be relatively stable over short periods of time. Thus, patients with EOP, RefP, and IDDM-AP all appear to have basal or resting-state monocytic responses that are ele-(2) One possible explanation for the large variance in the magnitude of mediator secretion in the normal population is vated with regard to PGE 2 production.
It is significant that AP, the most common periodontal condition that certain genetic polymorphisms are associated with a hypersecretory or hyposecretory monocytic trait (see [24, 25] for (accounting for Ç85% of all periodontal cases), is associated with a normal monocytic response (Mf N ), as determined with or review). Several of these stable genetic polymorphisms have been associated with increased severity of infectious or inwithout LPS challenge. Thus, cross-sectionally it would appear that subjects with AP have no evidence of monocytic abnormaliflammatory conditions, including cerebral malaria [25] , mucocutaneous leishmaniasis [26] , and psoriasis [27] . These polyties or ''priming'' as a consequence of genetic background or environmental exposures such as infection, including periodontal morphisms have been identified for IL-1 [28] and TNF-a [29] , both of which are capable of autocrine upregulation of monodisease. This would suggest that in AP, the microbial challenge that occurs systemically, albeit transient in nature, is not a sufficytic PGE 2 secretion. Thus, elevated PGE 2 secretion may be an indirect indicator or consequence of enhanced release of ILcient challenge to cause an upregulated, steady-state priming of the systemic peripheral blood monocyte.
1 or TNF-a. (3) Allelic variants in the IL-1 gene cluster result in altered It is not clear from these cross-sectional data whether, during episodes of acute disease progression, patients with AP have IL-1b response, and certain polymorphisms may be related to certain severe forms of AP [30] . Certain environmental expoa transiently upregulated monocyte phenotype. However, the close coupling of the local and systemic PGE 2 responses, as sures, such as smoking, may override any genetic contribution to disease expression. It is not known whether the increased demonstrated in figure 3, would suggest that previously reported transient elevations of mean GCF-PGE 2 levels (to 113. 4 disease susceptibility and high PGE 2 levels in the four highrisk patient groups in this study are a consequence of a hyperse-{ 9.0 ng/mL) [6] that occur during longitudinal episodes of disease progression are associated with a monocytic response cretory IL-1 and/or TNF-a polymorphism. (4) Environmental exposures such as smoking have been of 105 ng/mL (as computed with use of the regression function shown above). As can be seen, this value would theoretically demonstrated to enhance monocytic PGE 2 secretion [31] . Unfortunately, this important risk factor (see [32] for review) place the monocytic response in cases of AP breakdown equal to that in cases of RefP and EOP involving Mf / patients. was not uniformly determined for each subject in this study. Many of the subjects with RefP and three of the 16 subjects On the basis of the elevated GCF-PGE 2 levels during disease progression, these data suggest that during these short periods with TD-AP were smokers. Thus, smoking is one important potential mechanism for induction of a steady-state Mf / of active attachment loss, the patients with AP probably have a transient Mf / phenotype. This concept is further substantiphenotype.
(5) Metabolic lipid dysregulation upregulates monocytic reated by the observed hyperresponsive shift in the monocytic trait in TDP cases, as discussed below.
sponses to LPS challenge [33, 34] . Specifically, high levels of low density lipoprotein prime monocytes to secrete elevated Monocytes from the subjects with paroxysmal nocturnal hemoglobinuria who lack glycerolphosphatidyl inositol -anamounts of PGE 2 subsequent to challenge. Unfortunately, blood lipid chemistries were not included in our data collection. chored CD14 demonstrate a reduced PGE 2 secretory capacity,
